Literature DB >> 30763190

Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.

Suerie Moon1, Elise Erickson1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30763190     DOI： 10.1056/NEJMp1813728

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs.

Authors:  Bruce R Schackman; Zachary F Meisel
Journal:  Addiction       Date:  2019-10-23       Impact factor: 6.526

Review 2.  Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.

Authors:  Selin Ocal; Andrew J Muir
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

Review 3.  Hepatitis C elimination: a Public Health Perspective.

Authors:  Radha K Dhiman; Gagandeep S Grover; Madhumita Premkumar
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

Review 4.  Closing the hepatitis C treatment gap: United States strategies to improve retention in care.

Authors:  Austin T Jones; Christopher Briones; Torrence Tran; Lisa Moreno-Walton; Patricia J Kissinger
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517

5.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

6.  Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance.

Authors:  Mark W Douglas; Enoch S E Tay; Dao Sen Wang; Adrian T L Ong; Caroline Wilson; Amy Phu; Jen Kok; Dominic E Dwyer; Rowena A Bull; Andrew R Lloyd; Tanya L Applegate; Gregory J Dore; Anita Y Howe; Richard Harrigan; Jacob George
Journal:  Hepatol Commun       Date:  2020-04-06

Review 7.  Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin.

Authors:  Peiwen Zhang; Ran Guo; Jun Lian; Mengjia Zhi; Chengzhen Lu; Weishen Wu; Lihong Wang; Polin Chan; Zhongdan Chen; Jing Sun
Journal:  Ann Glob Health       Date:  2020-04-06       Impact factor: 2.462

8.  Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia.

Authors:  Hussain Abdulrahman Al-Omar; Abdulaziz Abdulhadi Attuwaijri; Ibrahim Abdulrahman Aljuffali
Journal:  Saudi Pharm J       Date:  2020-04-23       Impact factor: 4.330

9.  Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis.

Authors:  Michael J Zoratti; Ayesha Siddiqua; Rita E Morassut; Dena Zeraatkar; Roger Chou; Judith van Holten; Feng Xie; Eric Druyts
Journal:  EClinicalMedicine       Date:  2020-01-05

Review 10.  Innovations in Hepatitis C Screening and Treatment.

Authors:  Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami
Journal:  Hepatol Commun       Date:  2020-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.